Key facts
- Chai Discovery’s last known valuation is $1.3B (Dec 2025).
- It has raised $230.0M across 4 recorded rounds; the latest was Later Stage VC ($400.0M) in Jul 2026.
- Notable investors include General Catalyst, SV Angel, AWS Startups, Menlo Ventures, DCVC — 21 tracked in total.
- Status: Privately Held (backing).
Leadership
- Joshua MeierCo-Founder & CEO
- Jack DentCo-Founder & President
- Matt McPartlonCo-Founder
- Jacques BoitreaudCo-Founder
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Chai Discovery
Funding rounds
4 roundsAbout Chai Discovery
Developer of an AI-based molecular interactions platform designed for molecular structure prediction that performs state-of-the-art across tasks relevant to drug discovery. The company's platform operates models that can predict the structure of biochemical molecules and reprogram how they interact for developing new medications, enabling researchers to get unified predictions of proteins, small molecules, DNA, RNA, and covalent modifications.
- Industry
- Biotech
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 28
- Website
- chaidiscovery.com/
- Ownership
- Privately Held (backing)
Chai Discovery doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Chai Discovery shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Chai Discovery in its N-PORT filings yet. We sweep new filings monthly.